IPP Bureau

Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy
Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy

By IPP Bureau - January 22, 2024

GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients

Shilpa Medicare receives Europe approval for Amifampridine Tablets, 10 mg
Shilpa Medicare receives Europe approval for Amifampridine Tablets, 10 mg

By IPP Bureau - January 20, 2024

This product has sales of about US$ 20 million in Europe

AbbVie launches Produodopa for treatment of parkinson's disease in EU
AbbVie launches Produodopa for treatment of parkinson's disease in EU

By IPP Bureau - January 20, 2024

Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations

Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market

By IPP Bureau - January 19, 2024

Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets

Lupin receives USFDA’s approval for Febuxostat Tablets
Lupin receives USFDA’s approval for Febuxostat Tablets

By IPP Bureau - January 19, 2024

Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)

Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator
Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator

By IPP Bureau - January 19, 2024

Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator

Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg
Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg

By IPP Bureau - January 18, 2024

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis

NATCO invests US$ 2 million in Cellogen Therapeutics
NATCO invests US$ 2 million in Cellogen Therapeutics

By IPP Bureau - January 18, 2024

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy

Taro announces merger agreement with Sun Pharma
Taro announces merger agreement with Sun Pharma

By IPP Bureau - January 18, 2024

Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023

Torque Pharma reinvents healthcare dynamics with 'Better Together'
Torque Pharma reinvents healthcare dynamics with 'Better Together'

By IPP Bureau - January 18, 2024

The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme

Indoco Remedies receives EIR from USFDA for Goa Plant-I
Indoco Remedies receives EIR from USFDA for Goa Plant-I

By IPP Bureau - January 18, 2024

The PAI was conducted for two drug product applications (ANDAs) filed from this facility

Venus Remedies eceives GMP certification from Libya
Venus Remedies eceives GMP certification from Libya

By IPP Bureau - January 18, 2024

The certification underscores Venus Remedies Limited's adherence to stringent quality control measures

Dr. Agarwals Eye Hospital posts Q3 FY24 PAT at Rs. 9.44 Cr
Dr. Agarwals Eye Hospital posts Q3 FY24 PAT at Rs. 9.44 Cr

By IPP Bureau - January 18, 2024

The company has posted net profit of Rs.33.57 crores for the 9 Months period ended December 31, 2023

Piramal Pharma launches new concentration of Zinc Sulfate for Injection in U.S.
Piramal Pharma launches new concentration of Zinc Sulfate for Injection in U.S.

By IPP Bureau - January 17, 2024

The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio

Alkem Labs reports 'fraudulent transfer' of Rs 52 Cr
Alkem Labs reports 'fraudulent transfer' of Rs 52 Cr

By IPP Bureau - January 17, 2024

The company disclosed that several employees of a subsidiary had their business email addresses stolen

Latest Stories

Interviews

Packaging